Protypia
Founded in 2017 to apply emerging mass spectrometry proteomics to therapeutic discovery, Protypia provides a targeted quantitative proteomics platform to measure drug target systems in cells, tissue models and human tissues. The group supports target and biomarker identification, protein-level pharmacology and pathology integration across therapeutic areas from discovery through clinical development and collaborates with pharmaceutical, biotechnology and academic organizations. Protypia is now part of Inotiv.
Industries
Nr. of Employees
small (1-50)
Products
Targeted Proteomics Platform
A platform that quantifies drug target systems in various biological samples, integrating protein-level pharmacology and pathology across therapeutic areas.
MS Protein Analysis
A service that applies mass spectrometry to identify therapeutic targets and protein features related to drug resistance and response.
Targeted Proteomics Platform
A platform that quantifies drug target systems in various biological samples, integrating protein-level pharmacology and pathology across therapeutic areas.
MS Protein Analysis
A service that applies mass spectrometry to identify therapeutic targets and protein features related to drug resistance and response.
Services
Targeted proteomics platform
Targeted mass spectrometry service to quantify drug target systems in cell, tissue model and human tissue samples to inform discovery and development.
Proteomic target and biomarker discovery
Mass spectrometry-based identification and characterization of therapeutic targets and protein features associated with drug response or resistance.
Translational integration of proteomics with pathology
Integration of quantitative proteomics data with pathological assessment to inform pharmacology and development decisions.
Targeted proteomics platform
Targeted mass spectrometry service to quantify drug target systems in cell, tissue model and human tissue samples to inform discovery and development.
Proteomic target and biomarker discovery
Mass spectrometry-based identification and characterization of therapeutic targets and protein features associated with drug response or resistance.
Translational integration of proteomics with pathology
Integration of quantitative proteomics data with pathological assessment to inform pharmacology and development decisions.
Expertise Areas
- Proteomics for drug discovery
- Biomarker and target identification
- Translational pharmacology
- Tissue proteomics
Key Technologies
- Mass spectrometry-based proteomics
- Targeted quantitative proteomics
- Tissue proteomics
- Biomarker discovery workflows